Pfizer spinoff Cerevel to raise $445M in merger with blank-check company

Cerevel Therapeutics, a biotech firm spun out from Pfizer two years ago, will go public through an unorthodox and high-value merger with a blank-check company, taking advantage of a boom in such deals over the first half of this year.